Health and wellness products company Herbalife (NYSE: HLF) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.3% year on year to $1.28 billion. Guidance for next quarter’s revenue was better than expected at $1.28 billion at the midpoint, 1.4% above analysts’ estimates. Its non-GAAP profit of $0.45 per share was 5.6% below analysts’ consensus estimates.
Is now the time to buy HLF? Find out in our full research report (it’s free for active Edge members).
Herbalife (HLF) Q4 CY2025 Highlights:
- Revenue: $1.28 billion vs analyst estimates of $1.24 billion (6.3% year-on-year growth, 3.6% beat)
- Adjusted EPS: $0.45 vs analyst expectations of $0.48 (5.6% miss)
- Adjusted EBITDA: $156.1 million vs analyst estimates of $150.2 million (12.2% margin, 3.9% beat)
- Revenue Guidance for Q1 CY2026 is $1.28 billion at the midpoint, above analyst estimates of $1.26 billion
- EBITDA guidance for the upcoming financial year 2026 is $690 million at the midpoint, above analyst estimates of $680.9 million
- Operating Margin: 7.8%, down from 8.8% in the same quarter last year
- Market Capitalization: $1.71 billion
StockStory’s Take
Herbalife’s fourth quarter results were shaped by a combination of robust product innovation, regional sales momentum, and continued investment in its distributor network. Management highlighted India’s record quarterly net sales, attributed to the recent reduction in goods and services tax rates, and noted that enhanced digital tools and tailored training supported distributor engagement. CEO Stephan Gratziani credited ongoing product launches, such as MultiBurn and HL/Skin, and improved distributor retention for creating what he described as a “strong close to the year.”
Looking forward, Herbalife’s guidance is informed by upcoming product launches, further digital transformation, and a focus on personalized nutrition. Management is placing significant emphasis on the rollout of the Pro2col digital platform, which aims to blend data-driven insights with human connection to support customer health journeys. CFO John DeSimone cautioned that while Pro2col’s initial revenue contribution will be limited, its potential for long-term growth is substantial, stating, "there’s a lot more upside from vertical than risk."
Key Insights from Management’s Remarks
Management pointed to several region- and product-specific factors, as well as operational initiatives, that shaped quarterly performance and will influence the company’s outlook.
- India sales surge: India delivered its highest-ever quarterly net sales, fueled by a reduction in the goods and services tax on Herbalife products, which made offerings more affordable and spurred consumer demand.
- Distributor network expansion: North America saw a 19% increase in new distributors, while Latin America achieved its seventh consecutive quarter of distributor growth, reflecting the impact of enhanced training and digital engagement initiatives.
- Product innovation momentum: 2025 marked a year of accelerated product launches, including MultiBurn (weight management), HL/Skin (K-beauty skin care), and Life I/O Baseline (healthy lifespan), with management noting these launches as pivotal for attracting new customer segments.
- Digital ecosystem investment: The phased rollout of Pro2col, Herbalife’s health and wellness operating system, is designed to integrate personalized data and support distributor-customer relationships, with expanded beta access in North America and EMEA planned.
- Strategic partnerships: The announcement of Cristiano Ronaldo acquiring a 10% stake in Herbalife’s Pro2col subsidiary is aimed at increasing visibility and engagement for the company’s digital and personalized nutrition initiatives.
Drivers of Future Performance
Herbalife’s outlook is centered on the continued evolution of its product mix, distributor engagement, and the scaling of digital and personalized wellness platforms.
- Personalized nutrition focus: The commercial rollout of Pro2col and development of personalized supplements are expected to broaden Herbalife’s customer base, with management believing this approach will differentiate the brand in the evolving health and wellness landscape.
- Regional market strategies: Management expects sales growth in all regions except China, where recovery is projected beyond this year, and sees the GST tailwind in India as a key short-term driver until late 2026.
- Margin and cost considerations: Growth is supported by ongoing pricing benefits and volume gains, but margins face mild pressure from increased SG&A expenses, India GST-related costs, and continued investment in distributor events and digital platforms.
Catalysts in Upcoming Quarters
In future quarters, the StockStory team will be watching (1) the pace of adoption and monetization for Pro2col and personalized supplement offerings, (2) sustained distributor network growth and engagement, especially in North America and Latin America, and (3) the durability of India’s sales momentum as GST-driven benefits begin to normalize. Developments in strategic partnerships and the rollout of new product categories will also be key signposts for long-term growth.
Herbalife currently trades at $19.30, up from $16.54 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
